data (Page 6)

MicroStockHub X4 Pharmaceuticals (NASDAQ:XFOR) traded sharply lower on Thursday after the biotech updated data from an ongoing Phase 2 trial for its lead candidate mavorixafor in chronic neutropenia (CN), a rare blood disorder. Citing a May 24 data cut, the Boston, Massachusetts-based biotech said mavorixafor, which X4 (XFOR) markets asContinue Reading

This post is a follow-up to Generative AI and multi-modal agents in AWS: The key to unlocking new value in financial markets. This blog is part of the series, Generative AI and AI/ML in Capital Markets and Financial Services. Financial analysts and research analysts in capital markets distill business insightsContinue Reading

Md Saiful Islam Khan/iStock via Getty Images Annexon (NASDAQ:ANNX) shares traded higher on Wednesday after the company released additional data from its completed pivotal Phase 3 trial for its lead asset, ANX005, against the neurological disorder Guillain-Barré syndrome (GBS). Early this month, citing topline results from the study, the Brisbane,Continue Reading

Pgiam/iStock via Getty Images Oppenheimer downgraded respiratory device maker ResMed (NYSE:RMD) to Perform from Outperform on Tuesday, citing an “air pocket” for the stock in the wake of encouraging data for Eli Lilly’s (NYSE:LLY) weight loss therapy tirzepatide in obstructive sleep apnea (OSA). The maker of CPAP (continuous positive airwayContinue Reading